Onyx Pharmaceuticals, Inc. Message Board

bought 5K.

wow... desperate.

that's it.bottom line.

Localized USA
A number of other firms have also recently commented on ACAD. Analysts at MLV Capital raised their price target on shares of ACADIA Pharmaceuticals from $12.50 to $18.00 . They now have a “buy” rating on the stock. Separately, analysts at Roth Capital raised their price target on shares of ACADIA Pharmaceuticals from $15.00 to $20.00. They now have a “buy” rating on the stock. Analysts at Piper Jaffray upgraded shares of ACADIA Pharmaceuticals from a “neutral” rating to an “overweight” rating. Jefferies has raised their price target to $18 and have also said ACADIA makes an attractive licensing/ buyout target.

Seeking Alpha (Saturday )
5 Stocks To Watch For Gains This Week
Mar 30 2013 By: Brian Nichols
The drug, as currently approved, has market potential around $1 billion, judging by the success of Lovaza. Due to the success of its trial ANCHOR and the market potential of elevated triglyceride levels, which is eight times larger, I am not sure how Amarin is not a buy right now for the long term, in addition to short term. Assuming its indication is expanded, as I believe it will, I think the market is large enough for a bare minimum $1 billion in sales. Therefore, with the stock being very oversold, I wouldn't be surprised to see pop off its current bottom range next week. In addition, if $1 billion in sales is achieved (minimum) then the typical 3-4 times sales should also be expected, therefore presenting great upside.

not too bright.

Acadia shares rise as analyst sees drug approval
Shares of Acadia Pharma jump on confidence a top drug candidate will be approved
Associated PressAssociated Press –
NEW YORK (AP) -- Shares of Acadia Pharmaceuticals Inc. rose Monday on investor optimism about the prospects for its drug candidate pimavanserin, which is designed to treat psychosis in patients with Parkinson's disease.
Jefferies analyst Thomas Wei backed his "Buy" rating and $13 price target for the stock, saying that overall feedback on new data from a study of pimavanserin has been positive. The analyst said Jefferies spoke with 28 neurologists about the drug at a recent conference.

really low

good luck longs